

Is There a Genetic Relationship Between Arterial and Venous Thrombosis?

DOROTHY M ADCOCK

ABBREVIATIONS: ASVD = atherosclerotic vascular disease; DVT = deep venous thrombosis; GAIT = Genetic Susceptibility to Thrombosis; PE = pulmonary embolus; VTE = venous thromboembolic event.

INDEX TERMS: acute coronary syndrome; atherosclerotic vascular disease; deep vein thrombosis; lipids; myocardial infarction; pulmonary embolism; stroke; venous thromboembolic disease.

Clin Lab Sci 2007;(20)4:221

Dorothy M Adcock is medical director, Esoterix Coagulation, Aurora CO.

Address for correspondence: Dorothy M Adcock MD, medical director, Esoterix Coagulation, 8490 Upland Drive, Suite 100, Englewood CO 80112. (720) 568-4328, (720) 568-4314 (fax). dot.adcock@esoterix.com.

J Lynne Williams PhD CLS(NCA) is the Focus: New Directions in Homeostasis and Coagulation guest editor.

LEARNING OBJECTIVES

1. Correlate the clinical pathologic manifestations with the type of thrombosis (arterial vs venous).
2. Compare and contrast the most important risk factors, the nature of the clot, and the target for therapeutic prevention and treatment for arterial and venous clot formation.
3. Summarize the data suggesting a link between arterial and venous thrombosis.

The Focus section seeks to publish relevant and timely continuing education for clinical laboratory practitioners. Section editors, topics, and authors are selected in advance to cover current areas of interest in each discipline. Readers can obtain continuing education credit (CE) through P.A.C.E.® by completing the continuing education registration form, recording answers to the examination, and mailing a photocopy of it with the appropriate fee to the address designated on the form. Suggestions for future Focus topics and authors, and manuscripts appropriate for CE credit are encouraged. Direct all inquiries to the Clin Lab Sci Editorial Office, IC Ink, 858 Saint Annes Drive, Iowa City IA 52245. (319) 354-3861, (319) 338-1016 (fax). ic.ink@mchsi.com

Thromboembolic disease is the leading cause of morbidity and mortality in the developed world.¹ Arterial thrombosis is the most common underlying cause of acute myocardial infarction, non-hemorrhagic cerebrovascular accidents, and peripheral vascular disease. Pathological manifestations of venous thrombosis largely include deep venous thrombosis (DVT) and/or pulmonary embolus (PE). While arterial thromboembolic events are the foremost cause of death and disability, venous disease also plays an important role. DVT affects approximately two million Americans annually while PE is the most common cause of preventable hospital death accounting for 60,000 deaths in the United States annually.²

Medical textbooks and epidemiological studies characteristically consider arterial and venous thromboembolic disease as distinct entities, each with their own pathophysiological basis, unique risk factors, and distinct therapeutic regimens.³⁻⁶ Arterial clots typically occur in an injured vessel and the most common cause of vascular damage in the arterial system is atherosclerotic vascular disease (ASVD).³ The risk factors for arterial thrombosis are therefore considered the same as those for ASVD. Arterial clots occur in a high flow, high shear environment and these clots, also called white clots, are rich in platelets. Prevention and treatment of arterial thrombosis is often aimed at platelet inhibition. While vascular injury can promote the formation of venous clots, stasis and changes in blood composition (thrombophilia) are the most important risk factors for venous clot development.³ Venous clots occur in a low flow system. They are rich in fibrin that is enmeshed with red blood cells and are referred to as red clots. Inhibition of fibrin formation is the mainstay of prevention and treatment of venous thrombosis. It is often reported that the risk factors for arterial and venous thrombosis largely differ.^{5,6}

Is this distinction between arterial and venous thrombosis artificial? Is it a by-product of the fact that these entities often occur in different clinical settings and that they are treated differently and by different physician specialists? Have research and epidemiological studies, in evaluating arterial and venous disease as separate entities, perpetuated this segregated approach? Is it possible or perhaps likely that arterial and venous thromboembolic events actually represent different presentations of the same disease? While it is appreciated that

one may provoke the other as either can activate the hemostatic system, is the relationship between these entities in fact, more intimate?³ One important consideration supporting a close link is the well appreciated concept that both arterial and venous thrombosis are complex multi-factorial traits in which multiple genetic and acquired risk factors interact to determine risk.^{4,6,7} Do the risk factors for arterial and venous thrombosis share more in common than previously realized? If so, are there common genetic and acquired components? Indeed, recent studies, including a select few discussed below, have demonstrated a close association between these entities at a variety of levels. Specifically it has been shown that 1) arterial and venous thrombosis share common risk factors, 2) individuals that suffer idiopathic VTE are at a markedly increased risk of suffering a significant cardiovascular event, 3) individuals that suffer idiopathic VTE have an increased incidence of atherosclerotic vascular disease, and 4) those that suffer idiopathic VTE have a significantly higher incidence of metabolic syndrome.

The risk factors reported to be common to both arterial and venous thrombosis and that represent significant hazard for the development of each entity include increasing age and weight, smoking, exposure to estrogen, and the presence of diabetes. It has also been shown that high HDL cholesterol levels are associated with a decreased risk of venous thrombosis while elevated triglyceride and/or total cholesterol levels convey an increased risk.^{8,9} Other risk factors reported to be common to both arterial and venous thrombosis include the presence of antiphospholipid antibodies, dysfibrinogenemia, hyperhomocysteinemia, and elevated levels of fibrinogen, lipoprotein (a) and factor VIII.^{10,11}

A number of studies published recently have reported a strong link between arterial and venous thromboembolic disease. These studies have shown that patients who suffer an idiopathic venous thromboembolic event (VTE) are more likely to experience a significant arterial event than either the general population or those who suffered a provoked venous thrombosis.¹² In a 2005 study published in the *European Heart Journal*, of those who suffered their first idiopathic PE, 11% had a symptomatic arterial event with 12% mortality while those with a PE secondary to a known provocation suffered a 4% rate of symptomatic arterial events with 4% mortality. Another study published in 2006 reported that 11% of those who suffered an idiopathic VTE had a symptomatic arterial event with 8% mortality compared to 4% in the secondary VTE group with a 3% mortality rate. Likewise, Prandoni and others reported a 60% higher risk of suffer-

ing arterial events in those with idiopathic VTE than the cohort with VTE secondary to well-established risk factors after adjusting for age, hypertension, smoking, gender, and the presence of diabetes.¹³ Cardiovascular events therefore represent a major cause of morbidity and mortality in those individuals also at risk for idiopathic PE. This link supports a strong connection between arterial and venous thrombosis.¹² Given these reports, idiopathic PE can be considered an independent risk factor for cardiovascular disease.

In a recent study reported in the *New England Journal of Medicine*, patients with idiopathic VTE who were asymptomatic for atherosclerosis were studied using carotid ultrasound.¹⁴ Carotid plaques are considered a reliable indicator of atherosclerosis elsewhere in the circulation, in subjects without symptomatic atherosclerosis. Forty-seven percent of those individuals with idiopathic VTE had carotid plaque compared to twenty-seven percent with secondary DVT and thirty-two percent of controls.¹⁴ After noting this association between spontaneous VTE and atherosclerotic disease, the authors hypothesized that either one induces the other or else they share common risk factors.

There is an apparent association between metabolic syndrome, characterized by insulin resistance or glucose intolerance, hypertension, atherogenic dyslipidemia, central obesity, and the development of idiopathic VTE.¹⁵ It is well-established that those with metabolic syndrome are at significantly increased risk for the development of cardiovascular events. These individuals are also at risk for suffering spontaneous VTE. Ageno demonstrated that patients with idiopathic VTE had a higher incidence (51%) of metabolic syndrome than those without VTE (35%) or those that suffered VTE with known provocation.¹⁵ Should individuals with metabolic syndrome be more likely to receive thromboprophylaxis in situations of increased thrombotic risk than those without metabolic syndrome?

One of the strongest pieces of evidence in favor of a link between arterial and venous thrombosis is the Genetic Susceptibility to Thrombosis (GAIT) study.¹⁶ This family-based study of the genetics of thrombosis in a Spanish population was initiated to determine the heritability of thrombosis. Three hundred and twenty-eight individuals in 21 extended pedigrees were evaluated using a novel computer assisted adaptation of a multivariate threshold model. The authors concluded that more than 60% of the variation in susceptibility to common thrombosis is attributable to genetic factors. What makes this study unusual is that both

venous and arterial thromboembolic events were included in the analysis. When venous and arterial thrombosis were jointly analyzed as two distinct traits, the genetic correlation between these entities was not significantly different from one, and this strongly suggests that arterial and venous thromboses are highly genetically correlated. That is, many of the same genes are involved in the pathogenesis of arterial and venous disease.

The recent studies cited suggest that arterial and venous thrombosis represent different manifestations of the same disease and that the underlying process is driven by a common set of genes.^{15,16} The implications of these findings are significant with potential impact on many different areas of medicine from basic research to the various patient treatment regimens in current use. Transgenic and knock-out murine models evaluating thrombotic risk should evaluate risk of *both* arterial and venous disease, as should large family studies using genome wide linkage analysis. On a more practical note, the close link demonstrated between arterial and venous thrombosis suggests that patients who suffer idiopathic VTE should be closely evaluated for risk of all cardiovascular events and that individuals with atherosclerotic vascular disease should be monitored or in some circumstances provided prophylaxis for VTE. Future trials are needed to determine whether the long-term management of VTE should include prophylaxis against arterial cardiovascular events.

Clin Lab Sci encourages readers to respond with thoughts, questions, or comments regarding this article. Email responses to ic.ink@mchsi.com. In the subject line, please type "CLIN LAB SCI 20(4) FO ADCOCK". Selected responses will appear in the Dialogue and Discussion section in a future issue. Responses may be edited for length and clarity. We look forward to hearing from you.

REFERENCES

1. American Heart Association. 2005 Heart and Stroke Statistical Update. Dallas: American Heart Association; 2005.
2. Anderson FA Jr, Wheeler HB, Goldberg RJ, and others. A population based perspective of the hospital incidence and case-fatality rates of deep venous thrombosis and pulmonary embolus: the Worcester DVT study. *Arch Intern Med* 1991;151:933-8.
3. Lane DE, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial disease. *Blood* 2000;95:1517-32.
4. Bertina RM. Genetic approach to thrombophilia. *Thromb Haemost* 2001;86:92-103.
5. Bauer KA, Rosendaal FR, Heit J. Hypercoagulability: too many tests, too much conflicting data. *Hematology Am Soc Hematol Educ Program*. 2002:353-68.
6. Rosendaal FR. Venous thrombosis: a multicausal disease. *The Lancet* 1999;353:1167-7.
7. Heit JA, Phelps MA, Ward SA, Slusser JP, Petterson TM, De Andrade M. Familial segregation of venous thromboembolism. *J Thromb Haemost* 2004;2:731-6.
8. Doggen CJM, Smith NL, Lamaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. *Arterioscler Thromb Vasc Biol* 2004;24:1970-5.
9. Goldhaber SZ, Grodstein F, Stampfer MJ, and others. A prospective study of risk factors for pulmonary embolism in women. *JAMA* 1997; 277:642-5.
10. den Heijer M, Koster T, Blom HJ, and others. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. *New Eng J Med* 1996;334:759-62.
11. Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. *Thromb Haemost* 1997;78:967-8.
12. Becattini C, Agnelli G, Prandoni P, and others. A prospective study on cardiovascular events after acute pulmonary embolism. *European Heart Journal* 2005;26:77-83.
13. Prandoni P, Ghirarduzzi A, Prins MH, and others. Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis. *J Thromb Haemost* 2006;4:1891-6.
14. Prandoni P, Bilora F, Marchiori A, and others. An association between atherosclerosis and venous thrombosis. *New Engl J Med*. 2003;348:1435-41.
15. Ageno W, Prandoni P, Romualdi E, and others. The metabolic syndrome and the risk of venous thrombosis: a case-control study. *J Thromb Haemost* 2006;4:1914-8.
16. Souto JC, Almasry L, Borrell M, and others. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. *Am J Hum Genet* 2000;67:1452-9.
17. Jerjes-Sanchez C. Venous and arterial thrombosis: a continuous spectrum of the same disease? *European Heart Journal* 2005;26:3-4.